Pierre Bou Khalil

Pierre Bou Khalil

Auto-generated profile, based on publicly available information

Pierre Bou Khalil

Department of Internal Medicine, Division of Pulmonary and Critical Care, American University of Beirut Medical Center, Beirut, Lebanon

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2008 in Critical Care
Verified
Journal Article
Open access
PDF file
MEMohamad F El-Khatib
Mohamad F El-Khatib
PBPierre Bou-Khalil
Pierre Bou-Khalil
Mechanical ventilation is the defining event of intensive care unit (ICU) management. Although it is a life saving intervention in patients with acute respiratory failure and other disease entities, a major goal of critical care clinicians should be to liberate patients from mechanical ventilation as early as possible to avoid the multitude of complications and risks associated with prolonged unnecessary mechanical ventilation, including ventilator induced lung injury, ventilator associated pneumonia, increased length of ICU and hospital stay, and increased cost of care delivery. This review highlights the recent developments in assessing and testing for readiness of liberation from mechanical ventilation, the etiology of weaning failure, the value of weaning protocols, and a simple practical approach for liberation from mechanical ventilation.

20 September 2016 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
OHOssama K. Abou Hassan
Ossama K. Abou Hassan
MKMohamad Karnib
Mohamad Karnib
RERiyad El-Khoury
Riyad El-Khoury
Georges NemerGeorges Nemer
Georges Nemer
MAMamdouha Ahdab-Barmada
Mamdouha Ahdab-Barmada
PBPierre BouKhalil
Pierre BouKhalil
The recent rise in the use of linezolid to treat a variety of resistant pathogens has uncovered many side effects. Some patients develop lactic acidosis, myelosuppression, optic or peripheral neuropathies and myopathies. We evaluated an elderly patient who presented to the Emergency Room with linezolid toxicity and a novel neurologic complication characterized by bilateral globi pallidi necrosis. Mitochondrial ribosome inhibition was described to be the predisposing factor. The patient belongs to the mitochondrial J1 haplotype known to be associated with side effects of the drug. We recommend based on the molecular profile of the illness pretreatment considerations and complication management.

1 April 2008 in European Journal of Anaesthesiology
Verified
Journal Article
Closed access
MEM. F. El-Khatib
M. F. El-Khatib
AHAhmad Husari
Ahmad Husari
GJG. W. Jamaleddine
G. W. Jamaleddine
CAC. M. Ayoub
C. M. Ayoub
PBP. Bou-Khalil
P. Bou-Khalil
E of endotracheal tubes of sizes 7.5, 8.0 and 8.5 mm with different degrees and locations of endotracheal tube narrowing. Methods: Reductions of 10%, 25%, 50% and 75% in the endotracheal tube's cross-sectional areas were created at different sites along the axes of the tube connected to an artificial lung. While ventilating with a constant inspiratory flow, a 1 s end-inspiratory occlusion manoeuvre was applied and the resulting plateau pressure was determined. The resistance was calculated as (peak airway pressure - plateau pressure)/peak inspiratory flow. Results: Significant increases in the endotracheal tube's resistances were observed as the tube's cross-sectional area reduction was increased from 25% to 50% and from 50% to 75% for the 7.5 mm endotracheal tube, from 25% to 50% for the 8.0 mm endotracheal tube, and from 50% to 75% for the 8.5 mm endotracheal tube. Changes of the endotracheal tube resistances were not affected by the site of cross-sectional area reductions along the axes of the tubes. Conclusions: For endotracheal tubes of sizes 7.5, 8.0 and 8.5 mm, significant changes in the tubes resistances are observed when the partial obstructions of the tubes exceed certain critical values. The location of the partial obstruction did not affect the changes in the endotracheal tube resistances....

29 October 2018 in Critical Care
Verified
Journal Article
Open access
PDF file
BTBassem Y Tanios
Bassem Y Tanios
MOMaryam O Omran
Maryam O Omran
CNCarlos Noujeim
Carlos Noujeim
TLTamara Lotfi
Tamara Lotfi
SMSamir S Mallat
Samir S Mallat
HIHoussam S Itani
Houssam S Itani
Metabolic alkalosis is common in patients with respiratory failure and may delay weaning in mechanically ventilated patients. Carbonic anhydrase inhibitors block renal bicarbonate reabsorption, and thus reverse metabolic alkalosis. The objective of this systematic review is to assess the benefits and harms of carbonic anhydrase inhibitor therapy in patients with respiratory failure and metabolic alkalosis. We searched the following electronic sources from inception to August 2017: the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, and SCOPUS. Randomized clinical trials were included if they assessed at least one of the following outcomes: mortality, duration of hospital stay, duration of mechanical ventilation, adverse events, and blood gas parameters. Teams of two review authors worked in an independent and duplicate manner to select eligible trials, extract data, and assess risk of bias of the included trials. We used meta-analysis to synthesize statistical data and then assessed the certainty of evidence using the GRADE methodology. Six eligible studies were identified with a total of 564 participants. The synthesized data did not exclude a reduction or an increase in mortality (risk ratio (RR) 0.94, 95% confidence interval (CI) 0.57 to 1.56) or in duration of hospital stay (mean difference (MD) 0.42 days, 95% CI −4.82 to 5.66) with the use of carbonic anhydrase inhibitors. Carbonic anhydrase inhibitor therapy resulted in a decrease in the duration of mechanical ventilation of 27 h (95% CI −50 to −4). Also, it resulted in an increase in PaO2 (MD 11.37 mmHg, 95% CI 4.18 to 18.56) and a decrease in PaCO2 (MD −4.98 mmHg, 95% CI −9.66, −0.3), serum bicarbonate (MD −5.03 meq/L, 95% CI −6.52 to −3.54), and pH (MD −0.04, 95% CI −0.07 to −0.01). There was an increased risk of adverse events in the carbonic anhydrase inhibitor group (RR 1.71, 95% CI 0.98 to 2.99). Certainty of evidence was judged to be low for most outcomes. In patients with respiratory failure and metabolic alkalosis, carbonic anhydrase inhibitor therapy may have favorable effects on blood gas parameters. In mechanically ventilated patients, carbonic anhydrase inhibitor therapy may decrease the duration of mechanical ventilation. A major limitation of this finding was that only two trials assessed this clinically important outcome.

28 December 2023 in Respiratory Medicine
Verified
Journal Article
Closed access
JAJoseph Abourjeili
Joseph Abourjeili
ESElio Salameh
Elio Salameh
MNMaya Noureddine
Maya Noureddine
PKPierre Bou Khalil
Pierre Bou Khalil
AEAssaad Eid
Assaad Eid

19 March 2014 in Lung
Verified
Journal Article
Closed access
PDF file
MEMohamad F. El-Khatib
Mohamad F. El-Khatib
GJGhassan Jamaleddine
Ghassan Jamaleddine
NKNadim Kanj
Nadim Kanj
SZSalah Zeineddine
Salah Zeineddine
HCHassan Chami
Hassan Chami
PBPierre Bou-Khalil
Pierre Bou-Khalil